Cargando…

Circulating microRNAs Signature for Predicting Response to GLP1-RA Therapy in Type 2 Diabetic Patients: A Pilot Study

Type 2 diabetes (T2D) represents one of the major health issues of this century. Despite the availability of an increasing number of anti-hyperglycemic drugs, a significant proportion of patients are inadequately controlled, thus highlighting the need for novel biomarkers to guide treatment selectio...

Descripción completa

Detalles Bibliográficos
Autores principales:	Formichi, Caterina, Fignani, Daniela, Nigi, Laura, Grieco, Giuseppina Emanuela, Brusco, Noemi, Licata, Giada, Sabato, Claudia, Ferretti, Elisabetta, Sebastiani, Guido, Dotta, Francesco
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2021
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8431190/ https://www.ncbi.nlm.nih.gov/pubmed/34502360 http://dx.doi.org/10.3390/ijms22179454

Ejemplares similares

The Landscape of microRNAs in βCell: Between Phenotype Maintenance and Protection
por: Grieco, Giuseppina Emanuela, et al.
Publicado: (2021)

Non-Coding RNAs: Novel Players in Insulin Resistance and Related Diseases
por: Formichi, Caterina, et al.
Publicado: (2021)

Extracellular Vesicles in Immune System Regulation and Type 1 Diabetes: Cell-to-Cell Communication Mediators, Disease Biomarkers, and Promising Therapeutic Tools
por: Grieco, Giuseppina Emanuela, et al.
Publicado: (2021)

Targeting microRNAs as a Therapeutic Strategy to Reduce Oxidative Stress in Diabetes
por: Grieco, Giuseppina Emanuela, et al.
Publicado: (2019)

Protocol to analyze circulating small non-coding RNAs by high-throughput RNA sequencing from human plasma samples
por: Grieco, Giuseppina E., et al.
Publicado: (2021)

Reduced miR-184-3p expression protects pancreatic β-cells from lipotoxic and proinflammatory apoptosis in type 2 diabetes via CRTC1 upregulation
por: Grieco, Giuseppina E., et al.
Publicado: (2022)

Increased Expression of Viral Sensor MDA5 in Pancreatic Islets and in Hormone-Negative Endocrine Cells in Recent Onset Type 1 Diabetic Donors
por: Nigi, Laura, et al.
Publicado: (2022)

MicroRNAs as Regulators of Insulin Signaling: Research Updates and Potential Therapeutic Perspectives in Type 2 Diabetes
por: Nigi, Laura, et al.
Publicado: (2018)

MicroRNA Expression Analysis of In Vitro Dedifferentiated Human Pancreatic Islet Cells Reveals the Activation of the Pluripotency-Related MicroRNA Cluster miR-302s
por: Sebastiani, Guido, et al.
Publicado: (2018)

SARS-CoV-2 Receptor Angiotensin I-Converting Enzyme Type 2 (ACE2) Is Expressed in Human Pancreatic β-Cells and in the Human Pancreas Microvasculature
por: Fignani, Daniela, et al.
Publicado: (2020)

Intra-islet insulin synthesis defects are associated with endoplasmic reticulum stress and loss of beta cell identity in human diabetes
por: Brusco, Noemi, et al.
Publicado: (2022)

Circulating microRNA (miRNA) Expression Profiling in Plasma of Patients with Gestational Diabetes Mellitus Reveals Upregulation of miRNA miR-330-3p
por: Sebastiani, Guido, et al.
Publicado: (2017)

Pancreatic Alpha-Cells Contribute Together With Beta-Cells to CXCL10 Expression in Type 1 Diabetes
por: Nigi, Laura, et al.
Publicado: (2020)

Serum Levels of miR-148a and miR-21-5p Are Increased in Type 1 Diabetic Patients and Correlated with Markers of Bone Strength and Metabolism
por: Grieco, Giuseppina E., et al.
Publicado: (2018)

MicroRNA Expression in the Aqueous Humor of Patients with Diabetic Macular Edema
por: Grieco, Giuseppina Emanuela, et al.
Publicado: (2020)

Circulating MicroRNAs as Biomarkers of Gestational Diabetes Mellitus: Updates and Perspectives
por: Guarino, Elisa, et al.
Publicado: (2018)

MicroRNAs: Novel Players in the Dialogue between Pancreatic Islets and Immune System in Autoimmune Diabetes
por: Ventriglia, Giuliana, et al.
Publicado: (2015)

Identification and Validation of miR-222-3p and miR-409-3p as Plasma Biomarkers in Gestational Diabetes Mellitus Sharing Validated Target Genes Involved in Metabolic Homeostasis
por: Filardi, Tiziana, et al.
Publicado: (2022)

A Plasma miR-193b-365 Signature Combined With Age and Glycemic Status Predicts Response to Lactococcus lactis–Based Antigen-Specific Immunotherapy in New-Onset Type 1 Diabetes
por: Sassi, Gabriele, et al.
Publicado: (2023)

Regulatory T-cells from pancreatic lymphnodes of patients with type-1 diabetes express increased levels of microRNA miR-125a-5p that limits CCR2 expression
por: Sebastiani, Guido, et al.
Publicado: (2017)

Multi-Omics Integrative Approach of Extracellular Vesicles: A Future Challenging Milestone
por: Shaba, Enxhi, et al.
Publicado: (2022)

Circulating MicroRNAs in Elderly Type 2 Diabetic Patients
por: Catanzaro, Giuseppina, et al.
Publicado: (2018)

Basal insulin intensification with GLP-1RA and dual GIP and GLP-1RA in patients with uncontrolled type 2 diabetes mellitus: A rapid review of randomized controlled trials and meta-analysis
por: Lisco, Giuseppe, et al.
Publicado: (2022)

Elevated Circulating Fetuin-B Levels Are Associated with Insulin Resistance and Reduced by GLP-1RA in Newly Diagnosed PCOS Women
por: Mokou, Mani, et al.
Publicado: (2020)

FRAILTY AND THE COMPARATIVE EFFECTIVENESS AND SAFETY OF SGLT2I AND GLP1-RA IN OLDER ADULTS WITH TYPE 2 DIABETES
por: Patorno, Elisabetta, et al.
Publicado: (2019)

Monitoring the Comparative Safety of SGLT2i vs GLP-1 RA in Older Adults With Type 2 Diabetes by Frailty Status
por: Kutz, Alexander, et al.
Publicado: (2021)

SARS-CoV-2 Omicron symptoms and adverse effects of GLP-1 RA therapy
por: Jensterle, Mojca, et al.
Publicado: (2022)

The effect of GLP-1RA exenatide on idiopathic intracranial hypertension: a randomized clinical trial
por: Mitchell, James L, et al.
Publicado: (2023)

GLP-1 RA Improves Diabetic Retinopathy by Protecting the Blood-Retinal Barrier through GLP-1R-ROCK-p-MLC Signaling Pathway
por: Wei, Liufeng, et al.
Publicado: (2022)

Unexpected subcellular distribution of a specific isoform of the Coxsackie and adenovirus receptor, CAR-SIV, in human pancreatic beta cells
por: Ifie, Eseoghene, et al.
Publicado: (2018)

GLP-1 RA Treatment Patterns Among Type 2 Diabetes Patients in Five European Countries
por: Divino, Victoria, et al.
Publicado: (2017)

Efficacy of GLP-1 RA Approved for Weight Management in Patients With or Without Diabetes: A Narrative Review
por: Jensterle, Mojca, et al.
Publicado: (2022)

New Advances in Metabolic Syndrome, from Prevention to Treatment: The Role of Diet and Food
por: Ambroselli, Donatella, et al.
Publicado: (2023)

Glycemic monitoring with once-weekly Glucagon-like peptide 1 receptor agonist (GLP1RA) use
por: Kalra, Sanjay, et al.
Publicado: (2015)

The Role of Glucagon-Like Peptide-1 Receptor Agonists (GLP-1 RA) in Diabetes-Related Neurodegenerative Diseases
por: Cheng, Dihe, et al.
Publicado: (2022)

ODP171 Choosing GLP-1RA Over Insulin for Patients with Type 2 Diabetes and Severe Hyperglycemia
por: Mamtani, Raashi, et al.
Publicado: (2022)

GLP-1RA Liraglutide and Semaglutide Improves Obesity-Induced Muscle Atrophy via SIRT1 Pathway
por: Xiang, Jie, et al.
Publicado: (2023)

Circulating GLP-1 Levels in Patients with Pheochromocytoma/Paraganglioma
por: Chen, Nan, et al.
Publicado: (2022)

Real‐world GLP‐1 RA therapy in type 2 diabetes: A long‐term effectiveness observational study
por: Tofé, Santiago, et al.
Publicado: (2018)

Consensus Recommendations on GLP-1 RA Use in the Management of Type 2 Diabetes Mellitus: South Asian Task Force
por: Kalra, Sanjay, et al.
Publicado: (2019)

Cannot write session to /tmp/vufind_sessions/sess_96uu15s9ocs6be2hsnvesp9l9n